Mitotic cyclins and cyclin-dependent kinases in melanocytic lesions

Human Pathology

Volumn 29, Issue 10, 1998, Pages 1085-1090

  Tran, Tien Anh ^a   Ross, Jeffrey S ^a   Carlson, J Andrew ^a   Mihm Jr , Martin C ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Benign nevi; Cyclin A; Cyclin B; Immunohistochemical; Ki 67; Malignant melanoma; P34cdc2

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN A; CYCLIN B; CYCLIN DEPENDENT KINASE; KI 67 ANTIGEN;

ARTICLE; CANCER RECURRENCE; CELL CYCLE; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MELANOCYTE; MELANOCYTIC NEVUS; MELANOMA; MITOSIS; PATHOGENESIS; TREATMENT OUTCOME;

EID: 0031669830     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(98)90418-X     Document Type: Article

References (49)

1. Murray A, Hunt A: The Cell Cycle. New York, NY, WH Freeman, 1993
2. Pines J: Cyclins and cyclin-dependent kinases: A biochemical view. BiochemJ 308:697-711, 1995
3. Dirks PB, Rutka JT: Current concepts in neuro-oncology: The cell cycle - A review. Neurosurgery 40:1000-1015, 1997
4. Hunt T: Cyclins and their partners: From a simple idea to complicated reality (Review). Semin Cell Biol 2:213-222, 1991
5. Kobayashi H, Stewart E, Poon R, et al: Identification of the domains in cyclin A required for binding to, and activation of, p34cdc2 and p32cdc2 protein kinase subunits. Mol Biol Cell 3:1279-1294, 1992
6. Lees EM, Harlow E: Sequences within the conserved cyclin box of human cyclin A are sufficient for binding to and activation of cdc2 kinase. Mol Cell Biol 13:1194-1201, 1993
7. Hoffmann I, Clarke PR, Marcote MJ, et al: Phosphorylation and activation of human cdc25-C and cdc2-cyclin B and its involvement in the self-amplication of MPF at mitosis. EMBOJ 12:53-63, 1993
8. Sigrist S, Jacobs H, Stratmann R, et al: Exit from mitosis is regulated by Drosophila fizzy and the sequential destruction of cyclins A, B, and B3. EMBOJ 14:4827-4838, 1995
9. Nurse P, BissettY: Gene required in G1 for commitment to the cell cycle and in G2 for control of mitosis in fission yeast. Nature 292:558-560, 1981
10. Beach D, Durkacz B, Nurse P: Functionally homologous cell cycle control genes in budding and fission yeast. Nature 300:706-709, 1982
11. Hindley J, Phear GA: Sequence of the cell division gene cdc2 from Schizosaccharomyces pombe; patterns of splicing and homology to protein kinases. Gene 32:129-134, 1984
12. Lee EM, Nurse P: Complementation used to clone a human homologue of the fission yeast cell cycle control gene cdc2. Nature 327:31-35, 1987
13. Draetta G, Brizuela L, PotashkinJ, et ai: Identification of p34 and p13, human homologs of the cell cycle regulators of fission yeast encoded by cdc2+ and suc1+ . Cell 50:319-325, 1987
14. Lohka MJ, Hayes MK, Maller JL: Purification of maturationpromoting factor, an intracellular regulator of early mitotic events. Proc Natl Acad Sci U S A 85:3009-3013, 1988
15. Labbe JC, Capony JP, Caput D, et al: MPF from starfish oocytes at first meiotic metaphase is a heterodimer containing one molecule of cdc2 and one molecule of cyclin B. EMBO J 8:3053-3058, 1989
16. Gautier J, Minshull J, Lohka M, et al: Cyclin is a component of maturation-promoting factor from Xenopus. Cell 60:487-494, 1990
17. O'Connell MJ, Norbury C, Nurse P: Premature chromatin condensation upon accumulation of NIMA. EMBO J 13:4926-4937, 1994
18. Chambers TC, Langan TA: Purification and characterization of growth-associated H1 histone kinase from Novikoff hepatoma cells. J Biol Chem 265:16940-16947, 1990
19. Peter M, NakagawaJ, Doree M, et al: In vitro disassembly of the nuclear lamina and M phase-specific phosphorylation of lamins by cdc2 kinase. Cell 61:591-602, 1990
20. Heald R, McKeon F: Mutations of phosphorylation sites in lamin A that prevent nuclear lamina disassembly in mitosis. Cell 61:579-589, 1990
21. Luscher B, Brizuela L, Beach D, et al: A role for the p34cdc2 kinase and phosphatases in the regulation of phosphorylation and disassembly of lamin B2 during the cell cycle. EMBO J 10:865-875, 1991
22. Hamaguchi JR, Tobey RA, Pines J, et al: Requirement for p34cdc2 kinase is restricted to mitosis in the mammalian cdc2 mutant FT210. J Cell Biol 117:1041-1053, 1992
23. Bartkova J, Lucas J, Strauss M, et al: Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene 10:775-778, 1995
24. Cox DR: Regression models in life tables. J R Stat Soc 32:187-198, 1972
25. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1957
26. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (London) 366:704-707, 1993
27. Fountain JW, Karayiorgou M, Ernstoff MS, et al: Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci U S A 89:10557-10561, 1992
28. Goldstein AM, Dracopoli NC, Engelstein M, et al: Linkage of cutaneous malignant melanoma/dysplastic nevi to chromosome 9p and evidence for genetic heterogeneity. Am J Hum Genet 54:489-496, 1994
29. Kamb A, Shattuck-Eidens D, Eeles R, et al: Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 8:23-26, 1994
30. Zuo L, Weger J, Yang Q, et al: Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 12:97-99, 1996
31. Wang YL, Uhara H, Yamagazi Y, et al: Immunohistochemical detection of CDK4 and p16INK4 proteins in cutaneous malignant melanoma. BrJ Dermatol 134:269-275, 1996
32. Bartkova J, Lukas J, Guldberg P, et al: The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 56:5475-5483, 1996
33. Piccinin S, Dogliono C, Maestro R, et al: p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression. IntJ Cancer 74:26-30, 1997
34. Soyer HP: Ki-67 immunostaining in melanocytic skin tumors: Correlation with histologic parameters. J Cutan Pathol 18:264-272, 1991
35. Rieger E, Hofmann-Wellenhof R, Soyer P, et al: Comparison of proliferative activity as assessed by proliferating cell nuclear antigen (PCNA) and Ki-67 monoclonal antibodies in melanocytic lesions: A quantitative immunohistochemical study. J Cutan Pathol 20:229-236, 1993
36. Rudolph P, Schubert C, Schubert B, et al: Proliferation marker Ki-S5 as a diagnostic tool in melanocytic lesions. J Am Acad Dermatol 37:169-178, 1997
37. Santa Cruz DJ, Hamilton PD, Klos DJ, et al: Differential expression of metallopanstimullin/S27 ribosomal protein in melanocytic lesions of the skin. J Cutan Pathol 24:533-542, 1997
38. Niemann T, Argenyi Z: Immunohistochemical study of Spitz nevi and malignant melanoma with use of antibody to proliferating call nuclear antigen. AmJ Dermatopathol 15:441-445, 1993
39. Penneys N, Seigfried E, Nahass G, et al: Expression of proliferating cell nuclear antigen in Spitz nevus. J Am Acad Dermatol 32:964-967, 1995
40. Kanter-Lewensohn L, Hedblad MA, Wedje J, et al: Immunohistochemical markers for distinguishing Spitz nevi from malignant melanoma. Mod Pathol 10:917-920, 1997
41. Kaudewitz P, Braun-Falco O, Ernst M, et al: Tumor cell growth fractions in human malignant melanomas and the correlation to histopathologic tumor grading. Am J Pathol 134:1063-1068, 1989
42. Ostmeier H, Suter L: The Ki-67 antigen in primary human melanomas: Its relationship to mitotic rate and tumor thickness and its stability. Arch Dermatol Res 281:173-177, 1989
43. Vogt T, Zipperer KH, Vogt A, et al: p53-protein and Ki-67 antigen expression are both reliable biomarkers of prognosis in thick stage 1 nodular melanomas of the skin. Histopathology 30:57-63, 1997
44. Ramsay JA, From L, Iscoe NA, et al: MIB-1 proliferative activity is a significant prognostic factor in primary thick cutaneous melanomas. J Invest Dermatol 105:22-26, 1995
45. Boni R, Doguoglu A, Burg G, et al: MIB-1 immunoreactivity correlates with metastatic dissemination in primary thick cutaneous melanoma. J Am Acad Dermatol 35:416-418, 1996
46. Pagano M, Pepperkork R, Verde F, et al: Cyclin A is required at two points in the human cell cycle. EMBOJ 11:961-971, 1992
47. Barlat I, Fesquet D, Brechot C, et al: Loss of the G1-S control of cyclin A expression during tumor progression of Chinese hamster lung fibroblasts. Cell Growth Differ 4:105-113, 1993
48. Rieber M, Rieber MS: Cyclin-dependent kinase 2 and cyclin A interaction with E2F are targets for tyrosine induction of B16 melanoma terminal differentiation. Cell Growth Differ 5:1339-1346, 1993
49. Orlandi L, Zaffaroni N, Bearzatto A, et al: Effect of melphalan and hyperthemia on p34cdc2 kinase activity in human melanoma cells. BrJ Cancer 74:1924-1928